All In Biotech

Drug Trial Radar · NCT06016062

A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

A Multi-center Phase I/II Trial to Evaluate the Efficacy and Safety of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

221

Planned (sponsor's estimate)

Start

Sep 14, 2023

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of Phase I of this trial is to evaluate the safety, tolerability, maximum tolerated dose (MTD)/maximum administered dose (MAD) of RC148 in patients with locally advanced unresectable or metastatic solid tumors to determine the recommended Phase II dose (RP2D), and the secondary objective is to evaluate the PK and PD characteristics, immunogenicity and preliminary clinical efficacy of RC148. Phase II will primarily evaluate the efficacy of the RC148 combination regimen, and secondarily will assess safety and tolerability, PK characteristics, and immunogenicity. During the trial, investigators will also evaluate the potential correlation of biomarkers with efficacy.

Conditions

  • Solid Tumor

Interventions

  • RC148 MonotherapyDrug

    RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle

  • RC148+docetaxel Combination TherapyDrug

    RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle; Docetaxel will be administered as an IV infusion on Day 1 of each 3-week cycle.

  • RC148+RC48 Combination TherapyDrug

    RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle; RC48 will be administered as an IV infusion on Day 1 of each 2-week cycle.

  • RC148+RC88 Combination TherapyDrug

    RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle; RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle.

  • RC148/Bevacizumab+RC88 Combination TherapyDrug

    RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle; RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle; Bevacizumab will be administered as an IV infusion on Day 1 of each 3-week cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I:Maximum tolerated dose (MTD)/Maximum administered dose (MAD)Time frame: Subjects will be treated and observed for DLT through the end of the first cycle (Days 1-28)
  2. Phase I:DLTTime frame: 28 days after first treatment
  3. Phase I:The incidence and severity of adverse events (AE)Time frame: From the day of ICF sign to 28/90 days after the day of the last treatment
  4. Phase I:Recommended Phase 2 dose (RP2D)Time frame: 28 days or 1cycle
  5. Phase II: ORR, DCR, DoR, PFS based on RECIST v1.1 investigator assessment;Time frame: 15 months

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Anhui, China · Recruiting

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, China · Recruiting

  • Beijing University Cancer Hospital

    Beijing, China · Recruiting

  • The Fifth Medical Center of Chinese PLA General Hospital

    Beijing, China · Recruiting

  • Jilin Cancer Hospital

    Changchun, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, China · Recruiting

  • Hunan Second People's Hospital

    Changsha, China · Recruiting

  • Sichuan Cancer Hospital

    Chengdu, China · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, China · Recruiting

  • The Second Affiliated Hospital of Guilin Medical University

    Guilin, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Recruiting

  • Jinan Central Hospital

    Jinan, China · Recruiting

  • Qilu Hospital of shangdong university

    Jinan, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, China · Recruiting

  • Meizhou People's Hospital

    Meizhou, China · Recruiting

  • Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute

    Nanning, China · Recruiting

  • Nanyang City Center Hospital

    Nanyang, China · Recruiting

  • Nanyang Second General Hospital

    Nanyang, China · Recruiting

  • Shanghai Pulmonology Hospital

    Shanghai, China · Recruiting

  • Liaoning Cancer Hospital & Institute

    Shenyang, China · Recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, China · Recruiting

  • Shanxi Provincial Tumor Hospital

    Taiyuan, China · Recruiting

  • Tongji Hospital, Tongji Medical College of HUST, China

    Wuhan, China · Recruiting

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

    Wuhan, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China · Recruiting

  • Yunnan Cancer Hospital

    Yunnan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.